Overview
Use this article to understand the key differences between Wegovy® and Mounjaro®, including active ingredients, mechanisms of action, clinical evidence on effectiveness, and how treatment suitability is determined by an EU-registered doctor.
Active ingredients and mechanisms of action
Wegovy® and Mounjaro® are both prescription weight management medications administered via once-weekly subcutaneous self-injection, but they contain different active ingredients and target different hormone pathways:
Wegovy® (semaglutide): Contains the active ingredient semaglutide, which acts as a single GLP-1 (glucagon-like peptide-1) receptor agonist. It mimics the natural GLP-1 hormone to regulate appetite, increase satiety, and slow gastric emptying.
Mounjaro® (tirzepatide): Contains the active ingredient tirzepatide, which acts as a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor agonist. It mimics both intestinal hormones to regulate appetite, enhance feelings of fullness, and support blood sugar control.
Administration Frequency: Both medications are administered once weekly on the same day each week using a pre-filled injection pen.
Clinical trial evidence and treatment effectiveness
Both Wegovy® and Mounjaro® have been demonstrated to be effective treatments for weight management in clinical studies when combined with a reduced-calorie diet and increased physical activity. Individual weight loss results vary depending on patient adherence, lifestyle factors, and personal response to the medication.
Wegovy® (semaglutide) evidence: Clinical trial data demonstrate that approximately 70% of participants taking semaglutide achieved a weight loss of at least 10% of their body weight over 68 weeks, with approximately 50% losing 15% or more. In broad clinical populations, average weight loss with Wegovy® at maintenance doses is approximately 15%.
Mounjaro® (tirzepatide) evidence: Clinical trial data indicate that users reaching the highest dosage of tirzepatide achieved an average weight loss of up to 20% of their body weight over trial periods.
Individual variation: Clinical outcomes vary significantly between individuals. Achieving targeted weight loss depends on consistent medication adherence, caloric restriction, and regular exercise.
Determining clinical suitability and choosing a treatment
Selecting between Wegovy® and Mounjaro® is a medical decision that requires clinical evaluation:
Individual medical assessment: An EU-registered doctor evaluates your health questionnaire, Body Mass Index (BMI), medical history, current health conditions, and previous treatment experiences before determining if Wegovy® or Mounjaro® is suitable for you.
Non-promotional clinical approach: Neither treatment is universally superior for every patient. Factors such as side effect tolerance, target dosage progression, and medical history guide the prescribing doctor's clinical recommendation.
Additional Assistance
If you still need help after reviewing the information above, additional assistance is available.